StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

Equities research analysts at StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also commented on the company. TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Oppenheimer raised Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price for the company in a report on Monday, September 23rd. Royal Bank of Canada decreased their price target on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research report on Friday, October 25th. LADENBURG THALM/SH SH cut Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $4.00 target price on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Nine analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Price Performance

MRNS stock opened at $0.32 on Tuesday. Marinus Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $11.26. The stock has a market capitalization of $17.87 million, a price-to-earnings ratio of -0.13 and a beta of 1.26. The business’s fifty day moving average price is $1.08 and its two-hundred day moving average price is $1.26.

Institutional Trading of Marinus Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. Suvretta Capital Management LLC grew its holdings in Marinus Pharmaceuticals by 32.8% during the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after buying an additional 1,253,901 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Marinus Pharmaceuticals by 5.0% in the first quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock worth $25,366,000 after acquiring an additional 132,689 shares during the period. abrdn plc grew its holdings in Marinus Pharmaceuticals by 146.1% during the 3rd quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock valued at $4,679,000 after buying an additional 1,578,329 shares in the last quarter. GSA Capital Partners LLP lifted its holdings in shares of Marinus Pharmaceuticals by 409.4% in the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after buying an additional 817,050 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new position in Marinus Pharmaceuticals in the 2nd quarter valued at $813,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.